<DOC>
	<DOCNO>NCT02372383</DOCNO>
	<brief_summary>The purpose study determine antimycobacterial drug pharmacokinetics ( PK ) pharmacodynamics ( PD ) patient cystic fibrosis ( CF ) improve treatment nontuberculous mycobacterial ( NTM ) lung disease .</brief_summary>
	<brief_title>Improving Treatment Nontuberculous Mycobacterial Infection Cystic Fibrosis</brief_title>
	<detailed_description>The purpose study determine antimycobacterial drug pharmacokinetics ( PK ) pharmacodynamics ( PD ) patient cystic fibrosis ( CF ) improve treatment nontuberculous mycobacterial ( NTM ) lung disease . Aim 1 : Determine PK profile oral antimycobacterial drug ( azithromycin , rifampin ethambutol ) fasting condition take food plus supplemental pancreatic enzyme subject pancreatic insufficient , compare healthy control . Aim 2 : Begin investigate influence inflammation , host characteristic , drug metabolism PK antimycobacterial drug . Aim 3 : Estimate optimize dose regimen antimycobacterial drug Mycobacterium avium complex ( MAC ) use historic minimum inhibitory concentration ( MIC ) data model Mycobacterium tuberculosis MAC infection . The central goal study improve treatment NTM infection CF . Upon completion study investigator determine PK antimycobacterial drug alter CF . More importantly , investigator develop CF-specific guideline achieve therapeutic goal recommendation drug dosing ( include dose , dose frequency time relation meal supplemental pancreatic enzyme ) time therapeutic monitoring use future treatment NTM lung disease CF .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>CF Subject CF diagnosis define sweat chloride &gt; 60mEq/L and/or presence two diseasecausing CFTR mutation . Ages 16 year . Pancreatic insufficient status define previous fecal pancreatic elastase &lt; 100mcg/g stool and/or 2 diseasecausing CFTR mutation know associated pancreatic insufficiency , take supplemental pancreatic enzyme 10002500 lipase units/kg/meal . No positive NTM culture last 2 year . Pulmonary function : Most recent FEV1 &gt; 40 % predict . Willing participate comply study procedure , willingness parent legally authorize representative provide write informed consent subject less 18 year age . Healthy Control Ages 18 year . BMI 30 best match CF body type . Willing participate comply study procedure , willingness parent legally authorize representative provide write informed consent subject less 18 year age . CF Subject Allergy intolerance rifampin , ethambutol , azithromycin . Hepatic insufficiency define AST ALT great three time upper limit normal screening appointment . Previous surgical bowel resection . Previous lung transplant . Use medication know interact antimycobacterial drug level ; note , common interaction CF patient use itraconazole , voriconazole , ivacaftor . We subject hold H2 blocker proton pump inhibitor 3 day prior PK study day . Inability hold azithromycin : Subjects exclude chronic azithromycin immunomodulatory purpose ; however , ask subject hold azithromycin start screen visit , 2 week washout period prior Visit 2 , remain end Visit 3 ( 4 week total ) . Acute exacerbation : exclusion addition oral , IV , inhale antibiotic , acute gastrointestinal illness vomit diarrhea 2 week prior visit . No exclusion previously prescribe alternate chronic inhale oral antibiotic . We also exclude pregnant woman ( urine pregnancy test perform female day PK study ) decisionally challenge subject . Healthy Control Allergy intolerance rifampin , ethambutol , azithromycin . Hepatic insufficiency define AST ALT great three time upper limit normal screening appointment . Previous chronic GI disease surgical bowel resection . Use medication know interact antimycobacterial drug level . We subject hold H2 blocker proton pump inhibitor 3 day prior PK study day . Acute illness : exclusion respiratory illness require antibiotic gastrointestinal illness vomit diarrhea 2 week prior PK visit . We also exclude pregnant woman ( urine pregnancy test perform day PK study ) decisionally challenge subject .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Nontuberculous Mycobacteria</keyword>
	<keyword>Treatment</keyword>
</DOC>